—
C+
C+ The full Closelook — membership. Open the C+ overview

Revvity Inc. (RVTY) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Revvity Inc.

RVTY in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Revvity supplies instruments, reagents, software and diagnostic platforms used to screen for genetic disorders, infectious disease and early childhood conditions, and separately provides genomic workflow tools for drug discovery. It serves pharmaceutical companies, laboratories, academic institutions, public health authorities and hospitals. The company is based in Waltham, Massachusetts.
Where it sits in the stack
Revvity holds no seat in Rubin, our AI infrastructure index; it sits instead in the Diagnostics & Research sleeve of the wider Healthcare sector we track. Its business runs on laboratory testing and genomic screening demand rather than on the compute build-out, so it is not a constraint on or a customer of the AI stack itself.
Who it is priced against
The diary's records carry no defined peer group for Revvity. The name the market most often sets alongside it is Thermo Fisher Scientific, another supplier of instruments and reagents to laboratories and health-care researchers.
Why Closelook tracks it
Revvity is a constituent of the S&P 500 and does not carry a Closelook score, so no module has yet been built for it. The diary has quoted it once, in a Midday 10 edition, as one of several health-care and biotech names reaching new highs alongside broader market moves that day.
What the diary watches
The diary watches whether demand for early-detection diagnostics and genomic sequencing tools continues to support Revvity's testing and screening business, and whether future coverage brings it a defined peer group or a scored module.

Revvity Inc. (RVTY) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for RVTY, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 1 analyst action on the wire · latest: price target by KeyBanc, 2026-09-04

The Street on this name

Analyst actions and the latest print for RVTY from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target KeyBanc — target 165 from 125 Target raised to $165 from $125 (+26.3% to spot) 2026-09-04

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Who it is priced against Diagnostics & Research · United States · 8 names with week and year-to-date

Peer group

Diagnostics & Research · United States

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against RVTY on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return trailing yield 0.10%, semi-annual · last 0.0700 USD on 2026-04-17

Dividends and capital return

What RVTY pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.14 USD per share · a 0.10% yield on the 2026-09-17 close 2 distributions, paid twice a year 2026-09-17
  • Change on the year 0.0% against the prior twelve months prior twelve months 0.14 USD per share
  • Last distribution 0.0700 USD per share as the price series records it, within days of the ex-date 2026-04-17
  • By calendar year 2025: 0.21 USD (partial) · 2026: 0.0700 USD to date first distribution recorded in the three-year window: 2025-04-17

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Revvity Inc. (RVTY)?

Revvity Inc. trades as RVTY on the US exchange (United States) in the Closelook research universe, as of the registry build of 2026-09-18.

Is RVTY in a Closelook index?

Not currently — Revvity Inc. is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does RVTY trade against its moving averages?

Uptrend stack intact: Trades +22.7% vs the 50-day and +41.6% vs the 200-day average, 1.9% below the 52-week high and +80.7% off the 52-week low; a golden cross printed 63 sessions ago. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Revvity Inc. do?

Revvity supplies instruments, reagents, software and diagnostic platforms used to screen for genetic disorders, infectious disease and early childhood conditions, and separately provides genomic workflow tools for drug discovery. It serves pharmaceutical companies, laboratories, academic institutions, public health authorities and hospitals. The company is based in Waltham, Massachusetts. The diary's records carry no defined peer group for Revvity. The name the market most often sets alongside it is Thermo Fisher Scientific, another supplier of instruments and reagents to laboratories and health-care researchers.

Where does Revvity Inc. sit in the AI build-out?

Revvity holds no seat in Rubin, our AI infrastructure index; it sits instead in the Diagnostics & Research sleeve of the wider Healthcare sector we track. Its business runs on laboratory testing and genomic screening demand rather than on the compute build-out, so it is not a constraint on or a customer of the AI stack itself. Revvity is a constituent of the S&P 500 and does not carry a Closelook score, so no module has yet been built for it. The diary has quoted it once, in a Midday 10 edition, as one of several health-care and biotech names reaching new highs alongside broader market moves that day.

Does Revvity Inc. pay a dividend?

Revvity Inc. has paid 0.14 USD per share over the last twelve months, paid twice a year, a trailing yield of 0.10% on the 2026-09-17 close; the last distribution recorded in the price series was 0.0700 USD on 2026-04-17. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Revvity Inc. recently?

The most recent analyst action on Revvity Inc. on the Closelook wire is a price target by KeyBanc on 2026-09-04 (target 165 from 125). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

Where has Closelook written about Revvity Inc.?

Revvity Inc. appears in 1 Closelook piece, most recently Midday 10: A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000 (2026-08-21). What Closelook said most recently: Barchart's large-cap 52-week new-high list, as of 11:59 CDT, carries 31 names and reads like the ex-tech thesis printed as breadth: twelve are health care, biotech or pharma — ARGX, BDX, BIO, CORT, HALO, MRK, REGN, RVTY, THC, TVTX, TXG… (Midday 10, 2026-08-21). The "Mentioned on Closelook" block on this page lists the long reads, the reference entries and the dailies that name it.

What does this page show?

A live price chart with SMA overlays and drawing tools for RVTY, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Mentioned on Closelook 1 piece · newest: Midday 10, “A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000” (2026-08-21)

Mentioned on Closelook

Where RVTY appears in the diary — 1 piece, newest first. Every link is our own writing.

Dailies

Related in the Closelook universe

then Diagnostics & Research. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.